Neurogene Inc.NGNEEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Neurogene Inc. is a clinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies for patients with rare, genetically driven neurological disorders that have significant unmet medical needs, with its primary operating markets spanning North America and Europe.
NGNE Q3 FY2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-23.8M
Net Profit
$-21.0M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.99
Neurogene Inc. Q3 FY2025 Financial Summary
Neurogene Inc. reported revenue of $0 for Q3 FY2025, with a net profit of $-21.0M (down 3.6% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-21.0M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 FY2025 |
Neurogene Inc. Quarterly Revenue & Net Profit History
Neurogene Inc. results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $0 | — | $-21.0M | N/A |
| Q2 FY2025 | $0 | — | $-22.0M | N/A |
| Q3 FY2024 | $0 | — | $-20.2M | N/A |
| Q2 FY2024 | $925.0K | — | $-18.5M | -1999.1% |
Income Statement
| Q2 2024 | Q3 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|
| Revenue | $925000 | $0 | $0 | $0 |
| YoY Growth | N/A | N/A | N/A | N/A |
Balance Sheet
| Q2 2024 | Q3 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|
| Assets | $179.8M | $164.1M | $297.3M | $287.8M |
| Liabilities | $24.8M | $26.7M | $24.1M | $22.3M |
| Equity | $155.0M | $137.4M | $273.3M | $265.5M |
Cash Flow
| Q2 2024 | Q3 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|
| Operating CF | $-15.9M | $-15.6M | $-19.5M | $-19.5M |